ArticleBiochemistry and biophysics reports2026
Dual-transferred atmospheric-pressure plasma jet modulates matrix metalloproteinase expression in breast cancer stem cells.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer stem cells (BCSCs) are a highly aggressive subpopulation, driving tumor initiation, metastasis, and therapeutic resistance, largely through matrix metalloproteinases (MMPs)-mediated extracellular matrix remodeling. Here, we introduce a dual-transferred atmospheric-pressure plasma jet (DTAPPJ) platform designed to enhance plasma stability, reactive species delivery, and spatial controllability, enabling targeted modulation of BCSCs. The DTAPPJ system was evaluated using argon and helium as working gases, with direct plasma exposure for 120, 180, and 240 s. Voltage-power measurements confirmed stable plasma propagation and low energy consumption (<1 W). At the same time, optical emission spectroscopy revealed a sequential amplification of reactive oxygen and nitrogen species (RONS) across primary, secondary, and tertiary jets. Biologically, DTAPPJ exposure induced robust, time-dependent suppression of multiple MMP genes, including MMP-1, -2, -3, -7, -9, -10, -11, -13, and -14, with helium-driven plasma consistently outperforming argon. This repression correlated with significant reductions in BCSC viability and metabolic activity in the 3D culture system, highlighting the system's ability to overcome intrinsic antioxidant defenses. Mechanistically, DTAPPJ likely exerts its effects through the oxidative modulation of redox-sensitive transcription factors that regulate MMP expression, thereby collectively diminishing the invasive and metastatic potential. The dual-transfer architecture, incorporating floating copper electrodes, ensures safe operation, enhanced reactive species generation, and minimal thermal impact. Overall, our findings demonstrate that DTAPPJ represents a low-power, multi-targeted plasma modality capable of simultaneously suppressing MMP-mediated invasion and impairing BCSC viability, providing a promising strategy for translational anticancer applications and potential minimally invasive therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.